Standard Capital Markets is a non-banking financial company that provides personal, business, and education loans, alongside fee-based services like loan syndication and financial asset restructuring.
The company operates in a highly fragmented and commoditized lending market with no evidence of low-cost funding advantages or proprietary distribution; the extremely low ROCE of 0.3% despite high reported net margins suggests an inefficient use of capital and lack of competitive edge.
Management has focused on aggressive balance sheet expansion through preferential allotments and NCD issuances, yet the resulting returns on equity and capital are negligible, indicating that growth is being bought through dilution rather than operational excellence.
The collapse was precipitated by a liquidity crunch as the company's razor-thin interest coverage of 1.48 proved insufficient to service its massive 5x debt load during a modest credit cycle downturn. The aggressive AUM expansion from 423 Cr to 1318 Cr in a single year, built on unseasoned loans and negative cash conversion, resulted in a wave of defaults that wiped out the negligible 0.1% ROE. As the capital-raising treadmill stopped, the market realized the reported 21% net margins were an accounting mirage disconnected from actual cash flow, leading to a permanent impairment of capital.
RichFakir rates Standard Capital Markets Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Standard Capital Markets Ltd is trading about 67% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Standard Capital Markets Ltd is: Not rated. Poor business (score 26), but the valuation is low-confidence, so we are not calling it a bargain.
RichFakir's educational estimate of Standard Capital Markets Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →